In particular, the phase III Checkmate 057 trial5 first demonstrated a significant superiority in terms of objective response rate (ORR), OS, tolerability and QoL in favour of the anti-PD-1 nivolumab over docetaxel in pre-treated patients with non-squamous NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.